ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / HOWL / options
ANVS (35) SER (31) GANX (41) ATNM (43) ⌘ Pro Terminal β†’

Werewolf Therapeutics Inc. (HOWL) Options Positioning, Max Pain & Unusual Sweeps

$1.05 +6.48% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.06

Werewolf Therapeutics Inc. (HOWL) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ SELL / AVOID Cap $47.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HOWL Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is HOWL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Werewolf Therapeutics Inc. (NASDAQ: HOWL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.05 (+6.48% 1D, market cap $47.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, HOWL ranks #428 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does HOWL compare to ANVS and SER in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HOWL carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, ANVS (Annovis Bio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $48.2M) and SER (Serina Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M). Among the 5-stock peer group, HOWL leads on earnings multiple (N/A) while HOWL leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HOWL?
β–Ό

Per HOWL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001785530), Werewolf Therapeutics Inc. generated $169.9M in revenue (-17.6% YoY), -$60.8M in net income, and -$60.3M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.06 (+0.98%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (42/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D-
025507510042
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D+
Cash (4)Whales (11)SEC (10)Macro (12)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-7.6% Base Target
$1 Bull$1 Base$1 Bear
πŸ“¬ FREE HOWL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for HOWL)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
πŸ” WHY HOWL SCORES 42/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)

FRED Regime Γ— Technicals: 74% of 52W Range β€’ RSI-14 at 51.2 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Whale & Options Positioning+11/20 pts (26% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–Ό #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
34
Grade E$0.98+6.1% Next Q
Q2 (-2Q)
37
Grade E$1.04-5.8% Next Q
Q3 (-1Q)
39
Grade E$0.98+7.1% Next Q
Current
42
Grade D-$1.05-7% Hist 90D Ξ±
Trajectory: E (34) β†’ D- (42)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a HOWL Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While HOWL currently carries a cautious 42/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.97) and Max Pain ($1.10) forces dealer call-delta covering toward $1.40.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HOWLβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œHOWL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 42%NO 58%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (HOWL)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for HOWL.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HOWL)

  • βœ“Walkthrough of HOWL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
HOWL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +52.17%⚑ TESTING RESISTANCE
2026-11-03O $1.10H $1.10L $0.99C $1.05VOL 415.6K
RES: $1.10SUP: $0.53SMA50: $0.97SMA200: $0.68
$1.16$0.92$0.68$0.44$0.20RES $1.10SUP $0.53$1.052026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HOWL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ HOWL Butterfly Map β†’ + Track HOWL β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HOWL today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for HOWL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HOWL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HOWL)

Health Care Rank #428 of 1015 βš”οΈ ANVS vs HOWL Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (HOWL vs. ANVS, SER, GANX, ATNM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Werewolf Therapeutics Inc. (HOWL) ranks #428 by composite RQD confidence (42/100, grade D-) and #752 by equity capitalization ($47.9M). Within this direct 5-issuer industry benchmark cohort, HOWL leads on earnings valuation at N/A trailing P/E, while HOWL leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. ATNM currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with HOWL at 42/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HOWL ACTIVE
Werewolf Therapeutics Inc.
D- 42/100 β€” β€” -35.0% +6.48% $47.9M Benchmark Subject
ANVS
Annovis Bio Inc.
D- 35/100 β€” β€” -35.0% -4.42% $48.2M /anvs-vs-howl β†’
SER
Serina Therapeutics Inc.
E 31/100 β€” β€” -35.0% -4.64% $49.3M /ser-vs-howl β†’
GANX
Gain Therapeutics Inc.
D- 41/100 β€” β€” -35.0% 0.00% $49.3M /ganx-vs-howl β†’
ATNM
Actinium Pharmaceuticals Inc. (Delaware)
D- 43/100 β€” β€” -35.0% -3.38% $46.5M /atnm-vs-howl β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001785530 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Werewolf Therapeutics Inc. (HOWL) reported GAAP revenue of $169.9M (-17.6% vs. FY2024 revenue of $206.1M , and +49.8% cumulative change since FY2023) , GAAP net income of -$60.8M, operating cash flow of -$60.3M, and free cash flow of -$60.3M (-6.8% YoY). On the balance sheet, HOWL closed FY2025 with $69.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $169.9M -$60.8M -$60.3M -$60.3M $69.4M β€”
FY2024 (FY) 2024-12-31 $206.1M -$70.5M -$56.2M -$56.4M $126.9M β€”
FY2023 (FY) 2023-12-31 $113.4M -$37.4M -$32.6M -$32.6M β€” β€”

3. HOWL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HOWL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Werewolf Therapeutics Inc. (NASDAQ: HOWL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.05 (+6.48% 1D, market cap $47.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, HOWL ranks #428 in composite RQD confidence.

How does HOWL compare to ANVS and SER in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HOWL carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, ANVS (Annovis Bio Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $48.2M) and SER (Serina Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M). Among the 5-stock peer group, HOWL leads on earnings multiple (N/A) while HOWL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HOWL?

Per HOWL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001785530), Werewolf Therapeutics Inc. generated $169.9M in revenue (-17.6% YoY), -$60.8M in net income, and -$60.3M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HOWL trading relative to its 50-day, 200-day, and 52-week technical levels?

HOWL last traded at $1.05 (+6.48% on volume of 272,211 shares), positioning the stock +8.25% above its 50-day simple moving average ($0.97) and +54.41% above its 200-day simple moving average ($0.68). Across its 52-week range of $0.27 to $1.33, HOWL sits at the 73.6% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $1.18).

Direct Sub-Reports: HOWL RQD Cockpit HOWL 12M Forecast HOWL Earnings & Move HOWL Dividends & DRIP HOWL Insiders & 13F HOWL Whale Options HOWL Profit Sankey HOWL News & Why
ROARABLE RATING BRIEF β€’ RQD 42/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

HOWL β€” Werewolf Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Werewolf Therapeutics Inc. (HOWL) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.05 (+6.48% 1D, market capitalization $47.9M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Werewolf Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company's reported revenue is β€” in each of the listed periods, so its revenue model is not evident from the financials provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Werewolf Therapeutics Inc. (HOWL) reported $169.9M in annual revenue (up from $206.1M in FY2024, -17.6% YoY) and -$60.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($113.4M revenue, -$37.4M net income) through FY2025, HOWL scaled operating cash flow to -$60.3M and free cash flow to -$60.3M, backed by $69.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 11/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $0.27 – $1.33 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), HOWL carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can HOWL sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $169.9M and free cash flow of -$60.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is HOWL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

HOWL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Werewolf Therapeutics Inc. (HOWL) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to HOWL Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HOWL Bull vs. Bear Conversation Board β€” What's Your Call at $1.05?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HOWL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on HOWL:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $1.19 (+20.2%)
πŸ“Œ Pinned Debate

A GREEN-flagged upgrade headline to Strong Buy and a 2.5 Altman Z-Score point to institutional interest and a balance sheet that has no

Long HOWL at $0.99 targeting $1.19. A GREEN-flagged upgrade headline to Strong Buy and a 2.5 Altman Z-Score point to institutional interest and a balance sheet that has not yet deteriorated to distress levels.. Institutional whale score is 11/20 and the risk/reward vs. the $0.27 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 πŸ‚ BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER β€’ Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.84 (-15.2%)
Spot @ $0.99

With zero reported revenue, a -35% ROIC, a 0% FCF yield, and cash falling from $111.0M to $57.0M, the company is consuming capital with

Sitting on the sidelines or leaning short HOWL above $0.99. With zero reported revenue, a -35% ROIC, a 0% FCF yield, and cash falling from $111.0M to $57.0M, the company is consuming capital without a visible path to cash generation.. Until Fundamental Cash Engine (4/20) and FCF yield (0.0%) inflect higher, upside is capped near $1.43.

LIVE TAPE